MONARCH 1, a phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, in patients with refractory HR+/HER2− metastatic breast cancer - Dickler, M N; Tolaney, S M; Rugo, H S (Clin Cancer Res, 2017)